Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy
International Journal of Molecular Sciences · 15.02.2023 · 24 (4) · 3876
DOI: 10.3390/ijms24043876 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.02.2023. Verfasst von Odunayo O Mugisho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, University of Auckland, Auckland 1023, New Zealand. Hauptthemen laut MEDLINE: Connexin 43, Diabetic Retinopathy, Benzamides. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Auckland Medical Research Foundation, Neurological Foundation of New Zealand, Neurological Foundation of New Zealand First Postdoctoral Fellowship 2001 FFE and an AMRF Project.
Abstract (Originalsprache)
Diabetic retinopathy (DR), a microvascular complication of diabetes, is associated with pronounced inflammation arising from the activation of a nucleotide-binding and oligomerization domain-like receptor (NLR) protein 3 (NLRP3) inflammasome. Cell culture models have shown that a connexin43 hemichannel blocker can prevent inflammasome activation in DR. The aim of this study was to evaluate the ocular safety and efficacy of tonabersat, an orally bioavailable connexin43 hemichannel blocker, to protect against DR signs in an inflammatory non-obese diabetic (NOD) DR mouse model. For retina safety studies, tonabersat was applied to retinal pigment epithelial (ARPE-19) cells or given orally to control NOD mice in the absence of any other stimuli. For efficacy studies, either tonabersat or a vehicle was given orally to the inflammatory NOD mouse model two hours before an intravitreal injection of pro-inflammatory cytokines, interleukin-1 beta, and tumour necrosis factor-alpha. Fundus and optical coherence tomography images were acquired at the baseline as well as at 2- and 7-day timepoints to assess microvascular abnormalities and sub-retinal fluid accumulation. Retinal inflammation and inflammasome activation were also assessed using immunohistochemistry. Tonabersat did not have any effect on ARPE-19 cells or control NOD mouse retinas in the absence of other stimuli. However, the tonabersat treatment in the inflammatory NOD mice significantly reduced macrovascular abnormalities, hyperreflective foci, sub-retinal fluid accumulation, vascular leak, inflammation, and inflammasome activation. These findings suggest that tonabersat may be a safe and effective treatment for DR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, University of Auckland, Auckland 1023, New Zealand.
- School of Optometry and Vision Science, University of Auckland, Auckland 1023, New Zealand.
- Department of Ophthalmology, University of Auckland, Auckland 1023, New Zealand.
ORCID-Profile: Odunayo O Mugisho, Heather Lyon, Monica L Acosta, Colin R Green, Ilva D Rupenthal
Förderung
- Auckland Medical Research Foundation
- Neurological Foundation of New Zealand
- Neurological Foundation of New Zealand First Postdoctoral Fellowship 2001 FFE and an AMRF Project
- W&B Hadden
- Buchanan Charitable Foundation
Zitieren
APA
Mugisho, O. O., Aryal, J., Shome, A., Lyon, H., Acosta, M. L., Green, C. R., & Rupenthal, I. D. (2023). Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International Journal of Molecular Sciences, 24(4), 3876. https://doi.org/10.3390/ijms24043876
Vancouver
Mugisho OO, Aryal J, Shome A, Lyon H, Acosta ML, Green CR, et al. Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International Journal of Molecular Sciences. 2023;24(4):3876. doi:10.3390/ijms24043876
BibTeX
@article{Mugisho2023,
author = {Mugisho, Odunayo O and Aryal, Jyoti and Shome, Avik and Lyon, Heather and Acosta, Monica L and Green, Colin R and Rupenthal, Ilva D},
title = {Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {4},
pages = {3876},
doi = {10.3390/ijms24043876}
}
EUVIMED